2013;4:209. 10. Nemunaitis J, Barve M, Orr D, Kuhn J, Magee M, Lamont J, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology. 2014;87:21 –9. 11. Barve M, Barve R, Rao D, Rao J, Manning L, Adams N, et al. Case report: vigil therapy in pathology de ﬁned high-risk differ- entiated thyroid cancer compounded by post ablation high-risk factors. J Surg Oncol Clin Res. 2017;1:1005. 12. Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wall- raven G, et al. Three-year follow up of GMCSF/bi-shRNA(furin)DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing ’s sarcoma. Mol Ther. 2016; 24:1478 –83. 13. Manning L, Barve M, Wallraven G, Kumar P, Taquet N, Bognar E, et al. Assessment of Low Dose Vigil ®Engineered Autologous Tumor Cell (EATC) immunotherapy in patients with advanced solid tumors. Clin Oncol. 2017;2:1254. 14. Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, et al. Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil ®in frontline maintenance. Gynecol Oncol Rep. 2020;34:100648. 15. Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, et al. Gemogenovatucel-T (Vigil) immunotherapy as main- tenance in frontline stage III/IV ovarian cancer (VITAL): a ran- domised, double-blind, placebo-controlled, phase 2b trial. LancetOncol. 2020;21:1661 –72. 16. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell ”vaccine (FANG) in advanced cancer. Mol Ther. 2012;20:679 –86. 17. Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelialcarcinoma (IMvigor211): a multicentre, open-label, phase 3 ran- domised controlled trial. Lancet.